FORMER Permodalan Nasional Bhd (PNB) president and CEO Datuk Abdul Rahman Ahmad is expected to make a comeback at the country’s largest unit trust fund manager after being coaxed to return by chairman Raja Tan Sri Arshad Raja Tun Uda. It is understood that while Abdul Rahman was hesitan...

KPJ Healthcare Bhd Target price: RM1.86 OVERWEIGHT

（吉隆坡15日讯）马化工联药（DPHARMA，7148，主要板医疗保健）宣布，与英国可负担药业中心（CADT）和荷兰PAMOJA制药公司签署了谅解备忘录，以合作在我国进行药物再利用研究。马化工联药董事经理里奥纳德阿礼夫在文告中指出，此项合作主要是为现有药物研发新用法。“作为大马领先的保健品牌，我相信...

（吉隆坡14日讯）联合药业（DPHARMA，7148，主板保健股）与英国可负担药业中心（CADT）荷兰PAMOJA药业签署了解备忘录，合作在我国进行药物再利用研究。联合药业董事经理莱纳德在文告中表示，此项合作主要是为现有药物研发新用法。“作为大马领先的保健品牌，我相信这项研究能让患者在短时间内拥有过...

券商 ：兴业投银研究投资建议 ：买进目标价 ：1.41令吉闭市价 ：1.18令吉（截至3月8日）每股收益 ：9仙（2024财年预估）本益比 ：13.27倍（2024财年预估）股息收益率 ：2.0%（2024财年预估）ESG评分 ：3分（总分为4分）由于赚幅高于同行、政府对医疗保健领域的预算分配提高，...

KUALA LUMPUR: RHB research has recommended a buy call on Duopharma Biotech Bhd because it sees good prospects for the company in the medium to long term, supported by the rise in non-communicable diseases (NCD) and the growing number of ...

DUOPHARMA Biotech Bhd is set to report weaker revenue and earnings for the financial year ended Dec 31, 2023 (FY2023), its first annual profit decline in four years. This comes amid a double whammy of higher operational costs and a dip in demand, which group managing director and executive direct...

Duopharma Biotech Bhd aims to deliver a satisfactory performance in 2024, underpinned by the positive advancements and anticipated growth in the economy and industry.

（吉隆坡22日讯）由于营运成本上涨、消费者保健领域需求下滑，马化工联药（DPHARMA，7148，主要板医疗保健）截至12月底2023财年末季，净利按年挫跌50.5%至850万令吉，写下7年来最差季度表现。该公司向马证交所报备，末季营业额按年上涨10.2%至1亿6750万令吉。全年净利按年减少24....

Pharmaceutical company Duopharma Biotech Bhd said on Thursday its quarterly net profit more than halved to its lowest in seven years, hurt by lower margins and higher finance costs.

KUALA LUMPUR: Duopharma Biotech Bhd aims to deliver a satisfactory performance in 2024, underpinned by the positive advancements and anticipated growth in the economy and industry.

Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.

KUALA LUMPUR (Jan 19): RHB Investment Bank Bhd (RHB IB) has maintained its “overweight” rating on the healthcare sector, amid expectations the private healthcare sector’s earnings growth will persist into 2024.

KUALA LUMPUR: RHB research expects the private healthcare sector's earnings growth to persist into 2024.The investment bank said this is underpinned by relatively inelastic demand, rising health awareness among consumers, and a rapidly ageing society anchoring generic drugmakers' mid- ...

This article first appeared in The Edge Malaysia Weekly on January 8, 2024 - January 14, 2024 AMONG The Edge’s stock picks in 2023, Bermaz Auto Bhd, Tenaga Nasional Bhd (TNB) and Inari Amertron Bhd were the top performers, with total returns of 24%, 12.9% and 18.7% ...

Strong buying interest needed to end FBM KLCI profit-taking spreeGovindan Kaladher The local stock market ended the final trading week of 2023 on a whimper, with the lack of local market leads and most investors away for the Christmas and New ...

KUALA LUMPUR: Trend semasa peningkatan kes COVID-19 sejak beberapa minggu ini telah mendorong minat belian pelabur terhadap kaunter sarung tangan getah dan penjagaan kesihatan. Ini dapat disaksikan dengan kaunter Careplus Group Bhd dan Top Glove Corp Bhd menjadi antara kaunter ...

（吉隆坡18日讯）尽管新冠疫情升温，但投资者情绪未受太大影响，富时综合指数收市报1465.28点，全天升2.83点或0....

theedgemalaysia.com highlighted one stock with positive momentum and seven stocks with negative momentum at Bursa Malaysia's afternoon close on Friday.

（吉隆坡1日讯）联合药业（Duopharma Biotech Berhad）与新加坡公司RenalWorks Pte Ltd的子公司RenalWorks Malaysia私人有限公司合作，通过提供专有的RenalGenie电子健康记录（EHR）透析软件来增强透析服务。